Niyad™ (nafamostat mesylate)
Anticoagulation of the extracorporeal circuit for Continuous Renal Replacement Therapy (CRRT) and Intermittent Hemodialysis (IHD)
Key Facts
About Talphera
Talphera, formerly known as AcelRx Pharmaceuticals, has pivoted from acute pain management to a broader mission of developing products for medically supervised settings following the divestment of its acute pain product in 2023. The company's strategy centers on nafamostat, a serine protease inhibitor with anticoagulant, anti-inflammatory, and antiviral properties, creating a 'pipeline-in-a-product.' With Niyad granted FDA Breakthrough Device designation and top-line data expected by the end of 2025, Talphera is positioned to address a significant unmet need in renal care while exploring additional applications for its core asset.
View full company profile